Pain Therapeutics (PTIE) 2.05 $PTIE
Global Pain Therapeutics Drugs, Markets and Companies Report 2015 - Forecasts to 2024
PR Newswire Europe - Thu Feb 12, 8:56AM CST
DUBLIN, Feb .12, 2015 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/35hddr/pain_therapeutics [http://www.researchandmarkets.com/research/35hddr/pain_therapeutics]) has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/35hddr/pain_therapeutics] to their offering.
PTIE: 2.05 (+0.03)
Global Pain Therapeutics Drugs, Markets and Companies Report 2015-2024
GlobeNewswire - Thu Feb 12, 8:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/txgw6l/pain_therapeutics) has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.
PTIE: 2.05 (+0.03)
Global Pain Therapeutics Drugs, Markets and Companies 2015-2024
M2 - Thu Feb 12, 8:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/b69tlb/pain_therapeutics) has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering. This report describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain. Major segments of the pain market are arthritis, neuropathic pain and cancer pain. Because pain is a subjective sensation, it is difficult to evaluate objectively in clinical trials. Various tools for pain measurement are described, including brain imaging. Most of the currently used analgesic drugs fall into the categories of opioids and nonsteroidal antiinflammatory drugs such as COX-2 inhibitors. Non-opioid analgesics include ketamine, a N-methyl-D-aspartate receptor antagonist. Adjuvant analgesics include antidepressants and antiepileptic drugs used for the treatment of neuropathic pain. Management of pain is multidisciplinary and includes both pharmacological and non-pharmacological methods such as acupuncture, transcutaneous electrical nerve stimulation and surgery. Various pain syndromes require different approaches in management, for example, the main category of drugs for migraine are triptans such as sumatriptan. Drug delivery is an important consideration in pain treatment. Controlled release preparations provide a steady delivery of analgesics. Well-known non-injection methods such astransdermal, pulmonary and intranasal application have been used. Topical analgesics and local anesthetics are also available. Devices such as implanted pumps are used for delivery of drugs such as opioids intrathecally (introduction into spinal subarachnoid space by lumbar puncture) in patients with cancer pain. Advances in molecular and biological techniques are markedly advancing our undestanding of pain. Understanding the pathophysiology of pain is an important factor in discovery of rational therapies for pain. Advances in pharmacogenomics and pharmacogenetics are enabling the development of personalized approaches to the management of pain. Over 500 companies have been identified to be involved in developing or marketing pain therapeutics and 174 of these are profiled in the report along with 151 collaborations. These are a mix of pharmaceutical companies and biotechnology companies. The worldwide analgesic markets were analyzed for the year 2014 and projected to 2024. Calculations are based on the epidemiology of various painful conditions and the development of analgesic drugs and devices. Unfulfilled needs for analgesics are identified and strategies are outlined to develop markets for analgesic drugs. The report is supplemented with 71 tables, 22 figures, and 600 selected references to the literature. Key Topics Covered: Executive Summary 1. Basic Aspects of Pain 2. Assessment of Pain and Analgesics 3. Pharmacotherapy of Pain 4. Management of Pain 5. Drug Delivery for Pain 6. Drug Development for Pain 7. Safety, Regulatory and Legal issues of pain management 8. Pain Markets 9. Future of Pain Therapeutics 10. Companies Involved in Pain Therapeutics 11. References For more information visit http://www.researchandmarkets.com/research/b6...erapeutics Source: Jain PharmaBiotech
PTIE: 2.05 (+0.03)
Mild Pain Pipeline Insights Report 2015
M2 - Wed Jan 28, 9:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/4lcl43/mild) has announced the addition of the "Mild Pain-Pipeline Insights, 2015" subscription to their offering. This Mild Pain Pipeline Insights report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Mild Pain. This report provides information on the therapeutic development based on the Mild Pain dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Key Topics Covered: - Mild Pain Overview - Mild Pain Pipeline Therapeutics - Mild Pain Therapeutics under Development by Companies - Mild Pain Late Stage Products (Filed and Phase III) - Comparative Analysis - Mild Pain Mid Clinical Stage Products (Phase II) - Comparative Analysis - Mild Pain Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Mild Pain Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Mild Pain - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Mild Pain - Discontinued Products - Mild Pain - Dormant Products - Companies Involved in Therapeutics Development for Mild Pain - Appendix For more information visit http://www.researchandmarkets.com/research/4lcl43/mild
PTIE: 2.05 (+0.03)
Chemotherapy Induced Pain Pipeline Insights Report 2015
M2 - Tue Jan 20, 10:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/zszzrx/chemotherapy) has announced the addition of the "Chemotherapy Induced Pain-Pipeline Insights, 2014" subscription to their offering. This Chemotherapy Induced Pain-Pipeline Insights, 2015, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Chemotherapy Induced Pain. This report provides information on the therapeutic development based on the Chemotherapy Induced Pain dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Key Topics Covered: - Chemotherapy Induced Pain Overview - Chemotherapy Induced Pain Pipeline Therapeutics - Chemotherapy Induced Pain Therapeutics under Development by Companies - Chemotherapy Induced Pain Late Stage Products (Filed and Phase III) - Comparative Analysis - Chemotherapy Induced Pain Mid Clinical Stage Products (Phase II) - Comparative Analysis - Chemotherapy Induced Pain Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Chemotherapy Induced Pain Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Chemotherapy Induced Pain - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Chemotherapy Induced Pain - Discontinued Products - Chemotherapy Induced Pain - Dormant Products - Companies Involved in Therapeutics Development for Chemotherapy Induced Pain - Appendix For more information visit http://www.researchandmarkets.com/research/zs...emotherapy
PTIE: 2.05 (+0.03)
Pain Therapeutics' Remoxy Would Be A Good Fit For Any Of These Experienced Companies
Clinically Sound Investor - at Seeking Alpha - Wed Dec 03, 2:41PM CST
MNK: 115.01 (+2.51), JNJ: 99.62 (+1.18), ENDP: 84.01 (+1.12), ACT: 285.37 (+3.71), DRRX: 1.00 (+0.03), NVS: 102.20 (-0.17), PTIE: 2.05 (+0.03)
Alzheimer's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcdctm/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 210 companies are cited in this text including: - AB Science - AbbVie Inc. - AC Immune SA - CHA Bio & Diostech Co., Ltd. - Chase Pharmaceuticals Corporation - Clera Inc. - Eli Lilly and Company - EncephRx, Inc. - EndoCeutics, Inc. - Epigen Biosciences, Inc. - MediPost Co., Ltd. - Neuralstem, Inc. - Pain Therapeutics, Inc. - PALUMED S.A. - Panacea Pharmaceuticals, Inc. - PeptiDream Inc. - Peptron, Inc. - Pfizer Inc. - PharmatrophiX, Inc. - Pharnext SAS - Phenomenome Discoveries, Inc. - PhysioGenix, Inc. - Plexxikon Inc. - Prana Biotechnology Limited - Probiodrug AG - Proteome Sciences Plc - Suven Life Sciences Ltd. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/xcdctm/alzheimers
PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), ABBV: 58.05 (+1.00), PRAN: 1.09 (-0.55), PTIE: 2.05 (+0.03), CUR: 3.41 (+0.13)
Painkiller Remoxy (Oxycodone) May Still See An NDA Refiling By Mid-2015
Clinically Sound Investor - at Seeking Alpha - Tue Nov 25, 10:24AM CST
PTIE: 2.05 (+0.03)
President of Proove Biosciences, Brian Meshkin, Speaks at the 8th Annual Pain Therapeutics Summit
PRWeb - Tue Nov 11, 9:06AM CST
President and CEO of Proove Biosciences, Brian Meshkin, spoke at the 8th Annual Pain Therapeutics Summit on the Emerging Role of Genetics in Pain Management. The Annual Pain and Migraine Therapeutics Summit is the premier conference covering the field of pain research and emerging therapeutic methods. The event attracts leaders from the pharmaceutical, biotech, device and medical communities to learn about the cutting-edge advances in various treatments of pain. Mr. Meshkin was among a panel of speakers including key industry leaders and academic researchers concerning the latest drug discovery science and analysis of pain therapies.
PTIE: 2.05 (+0.03)
Pain Therapeutics lowers earnings 250% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 1:14PM CST
PTIE: 2.05 (+0.03)
Pain Therapeutics - Drugs, Markets and Companies
PR Newswire - Mon Nov 03, 7:02AM CST
Research and Markets has announced the addition of a new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.
PTIE: 2.05 (+0.03)
Pain Therapeutics' (PTIE) CEO Remi Barbier on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 8:37PM CDT
PTIE: 2.05 (+0.03)
Pain Therapeutics Reports Q3 2014 Financial Results
GlobeNewswire - Thu Oct 30, 3:51PM CDT
Pain Therapeutics, Inc. (Nasdaq
TIE) today reported financial results for Q3 2014. Net loss in Q3 2014 was $3.5 million, or $0.08 per share, compared to a net loss in Q3 2013 of $0.8 million, or $0.02 per share. Net cash used in Q3 2014 was $1.7 million. We continue to believe net cash usage for full calendar year 2014 may be about $12 million. At September 30, 2014, cash and investments were $43.2 million.
PTIE: 2.05 (+0.03)
Pain Therapeutics EPS of -$0.08
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:50PM CDT
PTIE: 2.05 (+0.03)
Nasdaq stocks posting largest volume increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LAYN: 7.93 (+0.22), TRNX: 25.32 (+0.12), DRRX: 1.00 (+0.03), CEMI: 3.96 (-0.04), PBCP: 10.40 (-0.05), PTIE: 2.05 (+0.03), AMDA: 0.65 (+0.01)
Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 8.90 (-0.02), KSS: 68.25 (-0.58), MU: 31.85 (-0.09), PFE: 34.64 (-0.23), HAL: 44.19 (+1.42), AMGN: 153.48 (+0.30), NQ: 3.95 (-0.03), RGC: 23.23 (+1.35), MS: 36.78 (-0.12), MSG: 78.72 (+0.53), NVAX: 8.80 (+0.40), CQB: 14.49 (unch), SRPT: 12.76 (+0.11), RCPT: 115.83 (-0.66), TWTR: 48.50 (+0.55), PTIE: 2.05 (+0.03)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:49AM CDT
GFA: 1.42 (+0.14), FST: 0.34 (-0.02), ZAZA: 2.17 (+0.08), EBR: 1.81 (unch), VTAE: 14.40 (+0.82), XGTI: 0.43 (+0.01), VBIV: 3.01 (+0.01), DRRX: 1.00 (+0.03), CEMI: 3.96 (-0.04), PBR: 6.98 (+0.44), CBDE: 0.90 (+0.06), OMEX: 0.79 (+0.04), LAYN: 7.93 (+0.22), SRPT: 12.76 (+0.11), CNIT: 3.42 (+0.08), AKBA: 9.32 (+0.51), CTP: 6.53 (+0.13), VPCO: 1.02 (+0.01), PTIE: 2.05 (+0.03)
Pfizer (PFE) Stock Falls After Dropping Pain Drug
at The Street - Mon Oct 27, 10:37AM CDT
Shares of Pfizer (PFE) are down after the pharmaceutical company decided to discontinue its agreement to develop and commercialize the drug Remoxy, an oral formulation of oxycodone.
PFE: 34.64 (-0.23), PTIE: 2.05 (+0.03)
Durect and Pain Therapeutics plunge after Pfizer backs out of Remoxy development
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:26AM CDT
PFE: 34.64 (-0.23), DRRX: 1.00 (+0.03), PTIE: 2.05 (+0.03)
Global Pain Therapeutics Drugs, Markets and Companies Report 2015 - Forecasts to 2024
PR Newswire Europe - Thu Feb 12, 8:56AM CST
DUBLIN, Feb .12, 2015 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/35hddr/pain_therapeutics [http://www.researchandmarkets.com/research/35hddr/pain_therapeutics]) has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/35hddr/pain_therapeutics] to their offering.
PTIE: 2.05 (+0.03)
Global Pain Therapeutics Drugs, Markets and Companies Report 2015-2024
GlobeNewswire - Thu Feb 12, 8:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/txgw6l/pain_therapeutics) has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.
PTIE: 2.05 (+0.03)
Global Pain Therapeutics Drugs, Markets and Companies 2015-2024
M2 - Thu Feb 12, 8:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/b69tlb/pain_therapeutics) has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering. This report describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain. Major segments of the pain market are arthritis, neuropathic pain and cancer pain. Because pain is a subjective sensation, it is difficult to evaluate objectively in clinical trials. Various tools for pain measurement are described, including brain imaging. Most of the currently used analgesic drugs fall into the categories of opioids and nonsteroidal antiinflammatory drugs such as COX-2 inhibitors. Non-opioid analgesics include ketamine, a N-methyl-D-aspartate receptor antagonist. Adjuvant analgesics include antidepressants and antiepileptic drugs used for the treatment of neuropathic pain. Management of pain is multidisciplinary and includes both pharmacological and non-pharmacological methods such as acupuncture, transcutaneous electrical nerve stimulation and surgery. Various pain syndromes require different approaches in management, for example, the main category of drugs for migraine are triptans such as sumatriptan. Drug delivery is an important consideration in pain treatment. Controlled release preparations provide a steady delivery of analgesics. Well-known non-injection methods such astransdermal, pulmonary and intranasal application have been used. Topical analgesics and local anesthetics are also available. Devices such as implanted pumps are used for delivery of drugs such as opioids intrathecally (introduction into spinal subarachnoid space by lumbar puncture) in patients with cancer pain. Advances in molecular and biological techniques are markedly advancing our undestanding of pain. Understanding the pathophysiology of pain is an important factor in discovery of rational therapies for pain. Advances in pharmacogenomics and pharmacogenetics are enabling the development of personalized approaches to the management of pain. Over 500 companies have been identified to be involved in developing or marketing pain therapeutics and 174 of these are profiled in the report along with 151 collaborations. These are a mix of pharmaceutical companies and biotechnology companies. The worldwide analgesic markets were analyzed for the year 2014 and projected to 2024. Calculations are based on the epidemiology of various painful conditions and the development of analgesic drugs and devices. Unfulfilled needs for analgesics are identified and strategies are outlined to develop markets for analgesic drugs. The report is supplemented with 71 tables, 22 figures, and 600 selected references to the literature. Key Topics Covered: Executive Summary 1. Basic Aspects of Pain 2. Assessment of Pain and Analgesics 3. Pharmacotherapy of Pain 4. Management of Pain 5. Drug Delivery for Pain 6. Drug Development for Pain 7. Safety, Regulatory and Legal issues of pain management 8. Pain Markets 9. Future of Pain Therapeutics 10. Companies Involved in Pain Therapeutics 11. References For more information visit http://www.researchandmarkets.com/research/b6...erapeutics Source: Jain PharmaBiotech
PTIE: 2.05 (+0.03)
Mild Pain Pipeline Insights Report 2015
M2 - Wed Jan 28, 9:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/4lcl43/mild) has announced the addition of the "Mild Pain-Pipeline Insights, 2015" subscription to their offering. This Mild Pain Pipeline Insights report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Mild Pain. This report provides information on the therapeutic development based on the Mild Pain dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Key Topics Covered: - Mild Pain Overview - Mild Pain Pipeline Therapeutics - Mild Pain Therapeutics under Development by Companies - Mild Pain Late Stage Products (Filed and Phase III) - Comparative Analysis - Mild Pain Mid Clinical Stage Products (Phase II) - Comparative Analysis - Mild Pain Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Mild Pain Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Mild Pain - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Mild Pain - Discontinued Products - Mild Pain - Dormant Products - Companies Involved in Therapeutics Development for Mild Pain - Appendix For more information visit http://www.researchandmarkets.com/research/4lcl43/mild
PTIE: 2.05 (+0.03)
Chemotherapy Induced Pain Pipeline Insights Report 2015
M2 - Tue Jan 20, 10:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/zszzrx/chemotherapy) has announced the addition of the "Chemotherapy Induced Pain-Pipeline Insights, 2014" subscription to their offering. This Chemotherapy Induced Pain-Pipeline Insights, 2015, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Chemotherapy Induced Pain. This report provides information on the therapeutic development based on the Chemotherapy Induced Pain dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Key Topics Covered: - Chemotherapy Induced Pain Overview - Chemotherapy Induced Pain Pipeline Therapeutics - Chemotherapy Induced Pain Therapeutics under Development by Companies - Chemotherapy Induced Pain Late Stage Products (Filed and Phase III) - Comparative Analysis - Chemotherapy Induced Pain Mid Clinical Stage Products (Phase II) - Comparative Analysis - Chemotherapy Induced Pain Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Chemotherapy Induced Pain Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Chemotherapy Induced Pain - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Chemotherapy Induced Pain - Discontinued Products - Chemotherapy Induced Pain - Dormant Products - Companies Involved in Therapeutics Development for Chemotherapy Induced Pain - Appendix For more information visit http://www.researchandmarkets.com/research/zs...emotherapy
PTIE: 2.05 (+0.03)
Pain Therapeutics' Remoxy Would Be A Good Fit For Any Of These Experienced Companies
Clinically Sound Investor - at Seeking Alpha - Wed Dec 03, 2:41PM CST
MNK: 115.01 (+2.51), JNJ: 99.62 (+1.18), ENDP: 84.01 (+1.12), ACT: 285.37 (+3.71), DRRX: 1.00 (+0.03), NVS: 102.20 (-0.17), PTIE: 2.05 (+0.03)
Alzheimer's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcdctm/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 210 companies are cited in this text including: - AB Science - AbbVie Inc. - AC Immune SA - CHA Bio & Diostech Co., Ltd. - Chase Pharmaceuticals Corporation - Clera Inc. - Eli Lilly and Company - EncephRx, Inc. - EndoCeutics, Inc. - Epigen Biosciences, Inc. - MediPost Co., Ltd. - Neuralstem, Inc. - Pain Therapeutics, Inc. - PALUMED S.A. - Panacea Pharmaceuticals, Inc. - PeptiDream Inc. - Peptron, Inc. - Pfizer Inc. - PharmatrophiX, Inc. - Pharnext SAS - Phenomenome Discoveries, Inc. - PhysioGenix, Inc. - Plexxikon Inc. - Prana Biotechnology Limited - Probiodrug AG - Proteome Sciences Plc - Suven Life Sciences Ltd. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/xcdctm/alzheimers
PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), ABBV: 58.05 (+1.00), PRAN: 1.09 (-0.55), PTIE: 2.05 (+0.03), CUR: 3.41 (+0.13)
Painkiller Remoxy (Oxycodone) May Still See An NDA Refiling By Mid-2015
Clinically Sound Investor - at Seeking Alpha - Tue Nov 25, 10:24AM CST
PTIE: 2.05 (+0.03)
President of Proove Biosciences, Brian Meshkin, Speaks at the 8th Annual Pain Therapeutics Summit
PRWeb - Tue Nov 11, 9:06AM CST
President and CEO of Proove Biosciences, Brian Meshkin, spoke at the 8th Annual Pain Therapeutics Summit on the Emerging Role of Genetics in Pain Management. The Annual Pain and Migraine Therapeutics Summit is the premier conference covering the field of pain research and emerging therapeutic methods. The event attracts leaders from the pharmaceutical, biotech, device and medical communities to learn about the cutting-edge advances in various treatments of pain. Mr. Meshkin was among a panel of speakers including key industry leaders and academic researchers concerning the latest drug discovery science and analysis of pain therapies.
PTIE: 2.05 (+0.03)
Pain Therapeutics lowers earnings 250% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 1:14PM CST
PTIE: 2.05 (+0.03)
Pain Therapeutics - Drugs, Markets and Companies
PR Newswire - Mon Nov 03, 7:02AM CST
Research and Markets has announced the addition of a new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.
PTIE: 2.05 (+0.03)
Pain Therapeutics' (PTIE) CEO Remi Barbier on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 8:37PM CDT
PTIE: 2.05 (+0.03)
Pain Therapeutics Reports Q3 2014 Financial Results
GlobeNewswire - Thu Oct 30, 3:51PM CDT
Pain Therapeutics, Inc. (Nasdaq
TIE) today reported financial results for Q3 2014. Net loss in Q3 2014 was $3.5 million, or $0.08 per share, compared to a net loss in Q3 2013 of $0.8 million, or $0.02 per share. Net cash used in Q3 2014 was $1.7 million. We continue to believe net cash usage for full calendar year 2014 may be about $12 million. At September 30, 2014, cash and investments were $43.2 million. PTIE: 2.05 (+0.03)
Pain Therapeutics EPS of -$0.08
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:50PM CDT
PTIE: 2.05 (+0.03)
Nasdaq stocks posting largest volume increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LAYN: 7.93 (+0.22), TRNX: 25.32 (+0.12), DRRX: 1.00 (+0.03), CEMI: 3.96 (-0.04), PBCP: 10.40 (-0.05), PTIE: 2.05 (+0.03), AMDA: 0.65 (+0.01)
Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 8.90 (-0.02), KSS: 68.25 (-0.58), MU: 31.85 (-0.09), PFE: 34.64 (-0.23), HAL: 44.19 (+1.42), AMGN: 153.48 (+0.30), NQ: 3.95 (-0.03), RGC: 23.23 (+1.35), MS: 36.78 (-0.12), MSG: 78.72 (+0.53), NVAX: 8.80 (+0.40), CQB: 14.49 (unch), SRPT: 12.76 (+0.11), RCPT: 115.83 (-0.66), TWTR: 48.50 (+0.55), PTIE: 2.05 (+0.03)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:49AM CDT
GFA: 1.42 (+0.14), FST: 0.34 (-0.02), ZAZA: 2.17 (+0.08), EBR: 1.81 (unch), VTAE: 14.40 (+0.82), XGTI: 0.43 (+0.01), VBIV: 3.01 (+0.01), DRRX: 1.00 (+0.03), CEMI: 3.96 (-0.04), PBR: 6.98 (+0.44), CBDE: 0.90 (+0.06), OMEX: 0.79 (+0.04), LAYN: 7.93 (+0.22), SRPT: 12.76 (+0.11), CNIT: 3.42 (+0.08), AKBA: 9.32 (+0.51), CTP: 6.53 (+0.13), VPCO: 1.02 (+0.01), PTIE: 2.05 (+0.03)
Pfizer (PFE) Stock Falls After Dropping Pain Drug
at The Street - Mon Oct 27, 10:37AM CDT
Shares of Pfizer (PFE) are down after the pharmaceutical company decided to discontinue its agreement to develop and commercialize the drug Remoxy, an oral formulation of oxycodone.
PFE: 34.64 (-0.23), PTIE: 2.05 (+0.03)
Durect and Pain Therapeutics plunge after Pfizer backs out of Remoxy development
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:26AM CDT
PFE: 34.64 (-0.23), DRRX: 1.00 (+0.03), PTIE: 2.05 (+0.03)
